<p>Bausch Health Companies Inc. (TSE:BHC - 免費報告) - Zacks Research 的股票分析師在 3 月 11 日星期三發佈的報告中上調了 Bausch Health Companies 2026 年第二季度每股收益（EPS）預期。Zacks Research 分析師團隊現在預測該公司本季度每股收益為 1.28 美元，高於之前的 1.27 美元預期。Bausch Health Companies 當前全年的共識預期每股收益為 5.55 美元。Zacks Research 還發布了 Bausch Health Companies 2027 年第三季度每股收益預期為 1.52 美元，以及 2028 財年的每股收益預期為 4.56 美元。</p>
<p>Bausch Health Companies (TSE:BHC - 獲取免費報告) 最近在 2 月 18 日星期三公佈了季度財報。該公司報告本季度每股收益為 C($0.41)。該季度的收入為 66.2 億加元。Bausch Health Companies 的淨利潤率為 1.82%，股本回報率為負 20.27%。</p>
<p>其他幾位股票分析師最近也對 BHC 發表了評論。Raymond James Financial 在 12 月 15 日星期一的研究報告中將 Bausch Health Companies 的評級上調至 “持有”。巴克萊在 12 月 8 日星期一的報告中也將 Bausch Health Companies 的評級上調至 “持有”。根據 MarketBeat.com 的數據，兩位股票研究分析師對該股票給予了 “持有” 評級，該股票的平均評級為 “持有”。</p>
<p><strong>查看我們對 Bausch Health Companies 的最新股票分析</strong></p>
<h2>Bausch Health Companies 股價下跌 6.5%</h2>
<p>BHC 股票在星期五開盤價為 6.89 加元。該公司的 50 日移動平均價格為 8.56 加元，200 日移動平均價格為 9.07 加元。該公司的速動比率為 0.58，流動比率為 1.47，負債權益比率為 -3,835.02。該公司的市值為 25.5 億加元，市盈率為 16.40，市盈增長比率為 0.21，貝塔值為 0.60。Bausch Health Companies 的 12 個月低點為 5.91 加元，12 個月高點為 11.97 加元。</p>
<h2>Bausch Health Companies 新聞匯總</h2>
<p>以下是本週影響 Bausch Health Companies 的主要新聞：</p>
<ul>
<li>積極情緒：Zacks 上調了近期季度預期：2027 年第三季度每股收益從 1.42 美元上調至 1.52 美元，2026 年第二季度每股收益從 1.27 美元上調至 1.28 美元——對近期增長預期的温和上行。文章標題</li>
<li>積極情緒：Zacks 還上調了其他幾個季度的預測：2027 年第一季度（1.09 → 1.11）和 2026 年第四季度（1.46 → 1.49），如果銷售/利潤率跟隨，這可能會支持即將公佈的季度業績。文章標題</li>
<li>中性情緒：Zacks 發佈了 2028 財年每股收益預期為 4.56 美元，並重申當前全年的共識/預期接近 5.55 美元——這些長期數據提供了背景，但距離近期市場反應較遠。文章標題</li>
<li>消極情緒：幾項顯著的下調：2027 年第四季度大幅下調（從 1.47 美元降至 1.32 美元）和 2027 年第二季度下調（1.32 → 1.20）——這些減少表明 Zacks 預計 2027 財年後期的增長放緩或利潤壓力。文章標題</li>
<li>消極情緒：Zacks 下調了其他多個預測，包括 2026 年第三季度（1.50 → 1.44）、2026 年第一季度（1.13 → 1.10）、2026 財年（5.37 → 5.32）和 2027 財年（5.30 → 5.15），表明預期收益低於之前的估計，並對估值施加下行壓力。文章標題</li>
</ul>
<h2>Bausch Health Companies 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Bausch Health Companies Inc 是一家全球公司，開發、製造和銷售一系列製藥、醫療器械和非處方產品，主要涉及眼健康、胃腸病學和皮膚病學等治療領域。我們正在履行我們的承諾，建立一家致力於推動全球健康的創新公司。我們大約 22000 名員工團結在改善人們生活的使命下，我們在大約 100 個國家直接或間接地製造和銷售醫療保健產品。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Bausch Health Companies</li>
<li>華爾街害怕的黃金圖表……</li>
<li>埃隆·馬斯克已經讓我成為 “富有的人”</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>白銀支付 20% 股息。此外 68% 股份收益</li>
<li>1500 家銀行剛剛把你的銀行賬户交給了美聯儲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9QkhD?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9QkhD"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Bausch Health Companies 嗎？</h2>
<p>在你考慮投資 Bausch Health Companies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bausch Health Companies 並不在名單上。</p>
<p>雖然 Bausch Health Companies 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>Zacks Research 將 Bausch Health Companies (TSE:BHC) 2026 年第二季度每股收益（EPS）預估從 1.27 美元上調至 1.28 美元，全年預估為每股 5.55 美元。該公司還預測 2027 年第三季度的收益為 1.52 美元，2028 財年的收益為 4.56 美元。儘管最近季度每股虧損為 0.41 加元，分析師仍對該股票維持 “持有” 評級，該股最近下跌了 6.5%。該公司的市值為 25.5 億加元，市盈率為 16.40，過去 12 個月的交易區間在 5.91 加元至 11.97 加元之間</p>

<p>Bausch Health Companies Inc. (TSE:BHC - Free Report) - Stock analysts at Zacks Research upped their Q2 2026 EPS estimates for shares of Bausch Health Companies in a report issued on Wednesday, March 11th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.28 for the quarter, up from their prior estimate of $1.27. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q3 2027 earnings at $1.52 EPS and FY2028 earnings at $4.56 EPS.</p>
<div class="lb-trans"><p>Bausch Health Companies Inc. (TSE:BHC - 免費報告) - Zacks Research 的股票分析師在 3 月 11 日星期三發佈的報告中上調了 Bausch Health Companies 2026 年第二季度每股收益（EPS）預期。Zacks Research 分析師團隊現在預測該公司本季度每股收益為 1.28 美元，高於之前的 1.27 美元預期。Bausch Health Companies 當前全年的共識預期每股收益為 5.55 美元。Zacks Research 還發布了 Bausch Health Companies 2027 年第三季度每股收益預期為 1.52 美元，以及 2028 財年的每股收益預期為 4.56 美元。</p>
</div><p>Bausch Health Companies (TSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 18th. The company reported C($0.41) EPS for the quarter. The company had revenue of C$6.62 billion during the quarter. Bausch Health Companies had a net margin of 1.82% and a negative return on equity of 20.27%.</p>
<div class="lb-trans"><p>Bausch Health Companies (TSE:BHC - 獲取免費報告) 最近在 2 月 18 日星期三公佈了季度財報。該公司報告本季度每股收益為 C($0.41)。該季度的收入為 66.2 億加元。Bausch Health Companies 的淨利潤率為 1.82%，股本回報率為負 20.27%。</p>
</div><p>Several other equities analysts also recently commented on BHC. Raymond James Financial raised Bausch Health Companies to a &#34;hold&#34; rating in a research report on Monday, December 15th. Barclays raised Bausch Health Companies to a &#34;hold&#34; rating in a report on Monday, December 8th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of &#34;Hold&#34;.</p>
<div class="lb-trans"><p>其他幾位股票分析師最近也對 BHC 發表了評論。Raymond James Financial 在 12 月 15 日星期一的研究報告中將 Bausch Health Companies 的評級上調至 “持有”。巴克萊在 12 月 8 日星期一的報告中也將 Bausch Health Companies 的評級上調至 “持有”。根據 MarketBeat.com 的數據，兩位股票研究分析師對該股票給予了 “持有” 評級，該股票的平均評級為 “持有”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Bausch Health Companies</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Bausch Health Companies 的最新股票分析</strong></p>
</div><h2>Bausch Health Companies Trading Down 6.5%</h2>
<div class="lb-trans"><h2>Bausch Health Companies 股價下跌 6.5%</h2>
</div><p>Shares of BHC stock opened at C$6.89 on Friday. The firm has a 50 day moving average price of C$8.56 and a two-hundred day moving average price of C$9.07. The company has a quick ratio of 0.58, a current ratio of 1.47 and a debt-to-equity ratio of -3,835.02. The company has a market capitalization of C$2.55 billion, a PE ratio of 16.40, a price-to-earnings-growth ratio of 0.21 and a beta of 0.60. Bausch Health Companies has a 12-month low of C$5.91 and a 12-month high of C$11.97.</p>
<div class="lb-trans"><p>BHC 股票在星期五開盤價為 6.89 加元。該公司的 50 日移動平均價格為 8.56 加元，200 日移動平均價格為 9.07 加元。該公司的速動比率為 0.58，流動比率為 1.47，負債權益比率為 -3,835.02。該公司的市值為 25.5 億加元，市盈率為 16.40，市盈增長比率為 0.21，貝塔值為 0.60。Bausch Health Companies 的 12 個月低點為 5.91 加元，12 個月高點為 11.97 加元。</p>
</div><h2>Bausch Health Companies News Roundup</h2>
<div class="lb-trans"><h2>Bausch Health Companies 新聞匯總</h2>
</div><p>Here are the key news stories impacting Bausch Health Companies this week:</p>
<div class="lb-trans"><p>以下是本週影響 Bausch Health Companies 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Zacks raised near‑term quarter estimates: Q3 2027 EPS was lifted from $1.42 to $1.52 and Q2 2026 EPS was nudged from $1.27 to $1.28 — modest upside to near‑term growth expectations. Article Title</li>
<li>Positive Sentiment: Zacks also bumped a few other quarterly forecasts: Q1 2027 (1.09 → 1.11) and Q4 2026 (1.46 → 1.49), which could support upcoming quarterly results if sales/margins follow. Article Title</li>
<li>Neutral Sentiment: Zacks published a FY2028 EPS outlook of $4.56 and reiterates a consensus/current full‑year estimate near $5.55 — these longer‑range figures provide context but are farther from near‑term market reaction. Article Title</li>
<li>Negative Sentiment: Several notable downward revisions: Q4 2027 cut substantially (from $1.47 to $1.32) and Q2 2027 cut (1.32 → 1.20) — these reductions suggest Zacks expects slower growth or margin pressure later in FY2027. Article Title</li>
<li>Negative Sentiment: Zacks trimmed multiple other forecasts including Q3 2026 (1.50 → 1.44), Q1 2026 (1.13 → 1.10), FY2026 (5.37 → 5.32) and FY2027 (5.30 → 5.15), signaling lower expected earnings vs prior estimates and applying downward pressure to valuation. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Zacks 上調了近期季度預期：2027 年第三季度每股收益從 1.42 美元上調至 1.52 美元，2026 年第二季度每股收益從 1.27 美元上調至 1.28 美元——對近期增長預期的温和上行。文章標題</li>
<li>積極情緒：Zacks 還上調了其他幾個季度的預測：2027 年第一季度（1.09 → 1.11）和 2026 年第四季度（1.46 → 1.49），如果銷售/利潤率跟隨，這可能會支持即將公佈的季度業績。文章標題</li>
<li>中性情緒：Zacks 發佈了 2028 財年每股收益預期為 4.56 美元，並重申當前全年的共識/預期接近 5.55 美元——這些長期數據提供了背景，但距離近期市場反應較遠。文章標題</li>
<li>消極情緒：幾項顯著的下調：2027 年第四季度大幅下調（從 1.47 美元降至 1.32 美元）和 2027 年第二季度下調（1.32 → 1.20）——這些減少表明 Zacks 預計 2027 財年後期的增長放緩或利潤壓力。文章標題</li>
<li>消極情緒：Zacks 下調了其他多個預測，包括 2026 年第三季度（1.50 → 1.44）、2026 年第一季度（1.13 → 1.10）、2026 財年（5.37 → 5.32）和 2027 財年（5.30 → 5.15），表明預期收益低於之前的估計，並對估值施加下行壓力。文章標題</li>
</ul>
</div><h2>Bausch Health Companies Company Profile</h2>
<div class="lb-trans"><h2>Bausch Health Companies 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.</p>
<div class="lb-trans"><p>Bausch Health Companies Inc 是一家全球公司，開發、製造和銷售一系列製藥、醫療器械和非處方產品，主要涉及眼健康、胃腸病學和皮膚病學等治療領域。我們正在履行我們的承諾，建立一家致力於推動全球健康的創新公司。我們大約 22000 名員工團結在改善人們生活的使命下，我們在大約 100 個國家直接或間接地製造和銷售醫療保健產品。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Bausch Health Companies</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Elon Musk already made me a “wealthy man”</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>Silver paying 20% dividend. Plus 68% share gains</li>
<li>1,500 Banks Just Handed the Fed Your Bank Account</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Bausch Health Companies</li>
<li>華爾街害怕的黃金圖表……</li>
<li>埃隆·馬斯克已經讓我成為 “富有的人”</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>白銀支付 20% 股息。此外 68% 股份收益</li>
<li>1500 家銀行剛剛把你的銀行賬户交給了美聯儲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9QkhD" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=TSE&amp;Symbol=BHC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bausch Health Companies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Bausch Health Companies 嗎？</h2>
</div><p>Before you consider Bausch Health Companies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Bausch Health Companies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bausch Health Companies 並不在名單上。</p>
</div><p>While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bausch Health Companies 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Zacks 研究對 TSE:BHC 的收益發布了樂觀的預期